Holen Sie sich die Stockscreener-App
5.66
15.28%
-1.08
Schlusskurs vom Vortag:
$6.74
Offen:
$6.7
24-Stunden-Volumen:
146.41K
Relative Volume:
1.27
Marktkapitalisierung:
$43.61M
Einnahmen:
$654.00K
Nettoeinkommen (Verlust:
$-49.50M
KGV:
-9.2787
EPS:
-0.61
Netto-Cashflow:
$-30.50M
1W Leistung:
-0.70%
1M Leistung:
+10.87%
6M Leistung:
-28.62%
1J Leistung:
-47.13%
1-Tages-Spanne:
$5.55
$6.83
1-Wochen-Bereich:
$5.50
$6.83
52-Wochen-Spanne:
$3.8181
$13.20
Clene Inc Stock (CLNN) Company Profile
Firmenname
Clene Inc
Sektor
Branche
Telefon
801-676-9695
Adresse
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-28 | Eingeleitet | Oppenheimer | Outperform |
Clene Inc Aktie (CLNN) Neueste Nachrichten
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data - StockTitan
Clene (NASDAQ:CLNN) Stock Quotes, Forecast and News Summary - Benzinga
Clene (NASDAQ:CLNN) Raised to “Strong-Buy” at EF Hutton Acquisition Co. I - Defense World
Clene Showcases Latest Advancements in Neurodegenerative Disease Treatment at H.C. Wainwright Conference - Vancity Buzz
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
EF Hutton sets price target on Clene shares with buy rating - Investing.com
Clene’s CNM-Au8 Aims to Revolutionize Treatment for Neurodegenerative Disorders - Vancity Buzz
The Globe and Mail - The Globe and Mail
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet - Yahoo Finance UK
Clene to Present at H.C. Wainwright Global Investment Conference, Highlighting Advances in Neurodegenerative Disease Treatment - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference - Yahoo Finance
Clene Advances Innovative Treatment for Neurodegenerative Diseases - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases - Yahoo Finance
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire Inc.
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases - MSN
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet - MSN
IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast - Yahoo Finance
Clene’s CNM-Au8 Shows Promise in ALS and MS Treatment, CEO Discusses Trial Results - Vancity Buzz
IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials - Yahoo Finance
How the (CLNN) price action is used to our Advantage - Stock Traders Daily
Oppenheimer analysts downgrades a Perform rating for Clene Inc (CLNN) - Knox Daily
IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions - Yahoo Finance
Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade - Yahoo Finance UK
IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode - Yahoo Finance
HC Wainwright Boosts Clene (NASDAQ:CLNN) Price Target to $31.00 - Defense World
HC Wainwright Brokers Increase Earnings Estimates for Clene Inc. (NASDAQ:CLNN) - Defense World
Clene submits new CNM-Au8 data to FDA ahead of upcoming meeting - ALS News Today
IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates - Yahoo Finance
IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. - GlobeNewswire
IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. - Yahoo Finance
A Guide To The Risks Of Investing In Clene Inc (CLNN) - Knox Daily
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates - MSN
Clene shares target boosted by H.C. Wainwright, 'clinical efficacy in ALS' noted - Investing.com Canada
Clene shares target boosted by H.C. Wainwright, 'clinical efficacy in ALS' noted - Investing.com
Clene Inc Inc. (CLNN) Price Performance: A Guide to Technical Indicators - The InvestChronicle
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights - wallstreet:online
Clene shares target boosted by H.C. Wainwright, 'clinical efficacy in ALS' noted - Investing.com UK
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights - StockTitan
Clene’s (CLNN) “Buy” Rating Reiterated at Canaccord Genuity Group - Defense World
Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS - StockTitan
Clene (NASDAQ: CLNN) Announces Participation In Canaccord Genuity 44th Annual Growth Conference - Barchart
Clene stock hits 52-week low at $4.19 amid sharp annual decline - Investing.com
Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company ... - Enid News & Eagle
Clene Inc. (NASDAQ:CLNN) Short Interest Update - Defense World
Clene Inc. regains compliance with Nasdaq listing standards By Investing.com - Investing.com Australia
Clene Inc. regains compliance with Nasdaq listing standards - Investing.com India
Clene Inc. regains compliance with Nasdaq listing standards - Investing.com
Clene Inc. regains compliance with Nasdaq listing standards By Investing.com - Investing.com South Africa
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Clene to submit new CNM-Au8 data to FDA ahead of meeting - ALS News Today
Finanzdaten der Clene Inc-Aktie (CLNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Clene Inc-Aktie (CLNN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| General Resonance LLC | 10% Owner |
Apr 30 '24 |
Sale |
0.42 |
13,000 |
5,416 |
15,326,712 |
| General Resonance LLC | 10% Owner |
May 01 '24 |
Sale |
0.40 |
13,000 |
5,148 |
15,313,712 |
| General Resonance LLC | 10% Owner |
Apr 24 '24 |
Sale |
0.33 |
10,000 |
3,278 |
15,349,712 |
| General Resonance LLC | 10% Owner |
Apr 09 '24 |
Sale |
0.39 |
22,500 |
8,674 |
15,428,212 |
| MATLIN DAVID J | Director |
Nov 10 '23 |
Buy |
0.41 |
250,002 |
102,501 |
7,043,686 |
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):